Liang Cheng, Director of Anatomic Pathology and Director of Molecular Pathology at Lifespan Academic Medical Center and Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared a post on LinkedIn:
“New State-of-the-Art Review: “The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies” – just published in the November issue of European Urology EU platinum by Dr. Benjamin Maughan and colleagues. It’s a great honor to be part of this amazing team!
Liquid biopsies offer many promising areas of potential clinical utility. We believe there is now sufficient validation to justify their use in patients with genitourinary cancers. We recommend somatic tumor testing for all patients with metastatic genitourinary malignancies, given both disease-specific and disease-agnostic indications. Such testing may also provide important prognostic insights that can guide patient counseling, though certain applications still require validation in prospective, biomarker-driven clinical trials. We strongly encourage the extensive use of liquid biopsy testing when indicated, aiming to improve outcomes and support further research.
The clinical utility of liquid biopsies is expected to expand further as additional indications are evaluated and validated. Future applications may include patient selection for adjuvant therapy in renal cell carcinoma and/or urothelial carcinoma, screening of high-risk populations, and new predictive assays for systemic therapy. Each new application will need to be validated in appropriately designed clinical studies as part of the ongoing effort to advance personalized medicine and improve patient outcomes.
The full article is available here.”
More posts featuring Liang Cheng.